127 related articles for article (PubMed ID: 8080453)
21. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
22. DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)].
Zákovská A; Nováková O; Balcarová Z; Bierbach U; Farrell N; Brabec V
Eur J Biochem; 1998 Jun; 254(3):547-57. PubMed ID: 9688265
[TBL] [Abstract][Full Text] [Related]
23. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents.
McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
Br J Cancer; 1993 May; 67(5):996-1000. PubMed ID: 8494733
[TBL] [Abstract][Full Text] [Related]
24. Effect of the amine non-leaving group on the structure and stability of DNA complexes with cis-[Pt(R-NH2)2(NO3)2].
Butour JL; Alvinerie P; Souchard JP; Colson P; Houssier C; Johnson NP
Eur J Biochem; 1991 Dec; 202(3):975-80. PubMed ID: 1765105
[TBL] [Abstract][Full Text] [Related]
25. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
[TBL] [Abstract][Full Text] [Related]
27. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
[TBL] [Abstract][Full Text] [Related]
28. DNA interactions of new antitumor aminophosphine platinum(II) complexes.
Neplechová K; Kaspárková J; Vrána O; Nováková O; Habtemariam A; Watchman B; Sadler PJ; Brabec V
Mol Pharmacol; 1999 Jul; 56(1):20-30. PubMed ID: 10385680
[TBL] [Abstract][Full Text] [Related]
29. In vivo biochemical indices of nephrotoxicity of platinum analogs tetraplatin, CHIP, and cisplatin in the Fischer 344 rat.
Smith MA; Smith JH; Litterst CL; Copley MP; Uozumi J; Boyd MR
Fundam Appl Toxicol; 1988 Jan; 10(1):62-72. PubMed ID: 3350230
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, cytotoxicity, cell uptake and DNA interstrand cross-linking of 4,4'-dipyrazolylmethane-linked multinuclear platinum anti-cancer complexes.
Wheate NJ; Cullinane C; Webster LK; Collins JG
Anticancer Drug Des; 2001; 16(2-3):91-8. PubMed ID: 11962517
[TBL] [Abstract][Full Text] [Related]
31. DNA modifications by a novel bifunctional trinuclear platinum phase I anticancer agent.
Brabec V; Kaspárková J; Vrána O; Nováková O; Cox JW; Qu Y; Farrell N
Biochemistry; 1999 May; 38(21):6781-90. PubMed ID: 10346899
[TBL] [Abstract][Full Text] [Related]
32. Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9).
Schweitzer VG; Rarey KE; Dolan DF; Abrams G; Litterst CJ; Sheridan C
Otolaryngol Head Neck Surg; 1986 Apr; 94(4):458-70. PubMed ID: 3086808
[TBL] [Abstract][Full Text] [Related]
33. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
Kasparkova J; Novakova O; Farrell N; Brabec V
Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
[TBL] [Abstract][Full Text] [Related]
34. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
35. Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity.
Plooy AC; van Dijk M; Lohman PH
Cancer Res; 1984 May; 44(5):2043-51. PubMed ID: 6538808
[TBL] [Abstract][Full Text] [Related]
36. Preclinical antitumor activity of orally administered platinum (IV) complexes.
Rose WC; Crosswell AR; Schurig JE; Casazza AM
Cancer Chemother Pharmacol; 1993; 32(3):197-203. PubMed ID: 8500224
[TBL] [Abstract][Full Text] [Related]
37. DNA interactions of bifunctional dinuclear platinum(II) antitumor agents.
Zaludová R; Zákovská A; Kasparková J; Balcarová Z; Kleinwächter V; Vrána O; Farrell N; Brabec V
Eur J Biochem; 1997 Jun; 246(2):508-17. PubMed ID: 9208945
[TBL] [Abstract][Full Text] [Related]
38. Characterisation of the DNA sequence specificity, cellular toxicity and cross-linking properties of novel bispyridine-based dinuclear platinum complexes.
Johnson BW; Murray V; Temple MD
BMC Cancer; 2016 May; 16():333. PubMed ID: 27225032
[TBL] [Abstract][Full Text] [Related]
39. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
40. Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes.
Kim WK; Kwon YE
Cancer Chemother Pharmacol; 2007 Jul; 60(2):237-43. PubMed ID: 17089165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
